We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Survivorship Study of Cancer Patients Who Received Cranial Radiation Therapy (SPiRiT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04567251
Recruitment Status : Suspended (Protocol amendment in progress)
First Posted : September 28, 2020
Last Update Posted : January 20, 2023
Sponsor:
Collaborators:
Allergan
Varian Medical Systems
Information provided by (Responsible Party):
Duke University

Brief Summary:
The primary objectives of this randomized, placebo-controlled, double-blind study are to 1) assess whether or not Namzaric® improves cognitive function in cancer survivors who received prior brain irradiation as part of their standard of care therapy and 2) assess the feasibility of using a digital symptom tracking application focused on Health Related Quality of Life (HRQoL) and cognition in cancer survivors who received brain irradiation. Exploratory objectives include assessing longitudinally the effect of Namzaric® on Patient Reported Outcomes (PROs) as reported in the clinic, including measures of health-related quality of life, cognition, and financial toxicity and evaluating the safety and tolerability of administering Namzaric® to cancer survivors who have received prior irradiation.

Condition or disease Intervention/treatment Phase
Brain Metastases, Adult Primary Brain Tumor Lung Cancer Drug: Namzaric® Drug: Placebo Phase 3

Detailed Description:
Patients who may participate in the study are cancer survivors who received cranial irradiation for conditions including, but not limited to: primary brain tumors, brain metastases, patients with lung cancer receiving prophylactic brain irradiation, and long-term survivors of pediatric cancers. Up to 102 patients will be randomized 1:1 so half the patients receive Namzaric® and half receive placebo. Patients on both arms will be taking Namzaric® or placebo for 17 weeks, including dose-escalation and tapering. Patients will use a symptom monitoring app, Noona® Healthcare Mobile PRO Application, to identify real-time select HRQoL and cognitive symptoms during Namzaric® vs placebo therapy. Patients will be instructed to log symptoms as often as relevant using their own personal devices, as well as be prompted to fill out the Patient-Reported Outcomes Measurement Information System Global Health Screen (PROMIS Global Health-10 and Edmonton Symptom Assessment Scale) during treatment (weeks 9 and 14). There will be no patient follow-up after completing or discontinuing the study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 108 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Survivorship Study of Cancer Patients Who Received Cranial Radiation Therapy: Focus on Health-Related Quality of Life and Cognition
Actual Study Start Date : December 28, 2021
Estimated Primary Completion Date : April 2024
Estimated Study Completion Date : April 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Namzaric® arm
Arm 1 will take daily Namzaric® for 17 weeks, including 3 weeks of dose-escalation, 12 weeks at a stable dose, and a 2 week taper.
Drug: Namzaric®

Namzaric® will be given for 17 weeks using the following dosing schedule:

7 mg memantine hydrochloride and 10 mg donepezil hydrochloride for 1 week, 14 mg memantine hydrochloride and 10 mg donepezil hydrochloride for 1 week, 21 mg memantine hydrochloride and 10 mg donepezil hydrochloride for 1 week, 28 mg memantine hydrochloride and 10 mg donepezil hydrochloride for 12 weeks, 14 mg memantine hydrochloride and 10 mg donepezil hydrochloride for 1 week, 7 mg memantine hydrochloride and 10 mg donepezil hydrochloride for 1 week.


Placebo Comparator: Placebo arm
Arm 2 will take daily placebo for 17 weeks, including 3 weeks of dose-escalation, 12 weeks at a stable dose, and a 2 week taper.
Drug: Placebo
Placebo drug, which will look identical to commercial Namzaric®, will be given for 17 weeks including a 3 week dose-escalation, 12 week maintenance period, and 2 week taper.




Primary Outcome Measures :
  1. Effect of Namzaric® on cognition among cancer survivors who received brain irradiation [ Time Frame: Baseline, 15 weeks ]
    Mean change between baseline and 15 weeks in the Brief Cognitive Assessment (BAC) composite cognitive score within each treatment group

  2. Feasibility of using a digital symptom tracking application on HRQoL and cognition in cancer survivors who received brain irradiation [ Time Frame: Baseline, 15 weeks ]
    A percentage of patients returning for their 15 week clinic appointment who initiate a PROMIS questionnaire via the mobile application at weeks 9 and 14



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Cancer survivors who received cranial irradiation including, but not limited to, primary brain tumor, brain metastases, lung cancer receiving prophylactic brain irradiation, long-term survivors of pediatric cancers
  2. Initial radiation must have been completed more than 6 months prior to enrollment. Acceptable radiation therapies include fractionated partial brain irradiation, whole brain irradiation, or stereotactic radiosurgery (for any modality at least a total cumulative dose of 20 Gy) of at least 20 Gy
  3. Age ≥ 18 years at the time of entry into the study
  4. Karnofsky performance score (KPS) ≥ 70 or Eastern Cooperative Oncology Group (ECOG) grade ≤ 2
  5. No imaging evidence of disease progression within 4 months of enrollment
  6. Life expectancy > 6 months
  7. Access to a smartphone, tablet, or computer with capability to utilize the mobile symptom-tracking application
  8. Signed informed consent approved by the Institutional Review Board
  9. Subject must be fluent in English

Exclusion Criteria:

  1. Active psychiatric illness
  2. Clinically significant renal disease or insufficiency at the time of screening
  3. History of severe liver disease or laboratory values for liver function tests > 2.5 times the upper limit of normal at screening
  4. Use of cognition-enhancing medications at the time of screening. If patients have used cognition-enhancing medications in the past, a wash-out period can be considered for screening of 8 weeks at the discretion of the PI.
  5. Allergy to Namzaric or any of the components of Namzaric.
  6. Pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04567251


Locations
Layout table for location information
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27710
Sponsors and Collaborators
Duke University
Allergan
Varian Medical Systems
Investigators
Layout table for investigator information
Principal Investigator: Katherine Peters, MD, PhD Duke University
Additional Information:
Layout table for additonal information
Responsible Party: Duke University
ClinicalTrials.gov Identifier: NCT04567251    
Other Study ID Numbers: Pro00102684
First Posted: September 28, 2020    Key Record Dates
Last Update Posted: January 20, 2023
Last Verified: January 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Duke University:
Pro00102684
Katherine Peters
Lung Cancer
Brain metastases
Brain tumor
Radiation
Solid tumor
Namzaric®
Cognition
Pediatric Cancer
Cancer Survivor
Survivorship
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasm Metastasis
Brain Neoplasms
Neoplasms by Site
Neoplasms
Neoplastic Processes
Pathologic Processes
Central Nervous System Neoplasms
Nervous System Neoplasms
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases